{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:36:24Z","timestamp":1790390184643,"version":"4.1.0"},"reference-count":36,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2017,2,18]],"date-time":"2017-02-18T00:00:00Z","timestamp":1487376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Multiple myeloma (MM) is a hematological neoplasm characterized by the clonal proliferation of malignant plasma cells in the bone marrow. MM results in diffuse or focal bone infiltration and extramedullary lesions. Over the past two decades, advances have been made with regard to the diagnosis, staging, treatment, and imaging of MM. Computed tomography (CT) and magnetic resonance imaging (MRI) are currently recommended as the most effective imaging modalities at diagnostic. Yet, recent data from the literature suggest that positron emission tomography combined with computed tomography (PET\/CT) using 18F-deoxyglucose (FDG) is a promising technique for initial staging and therapeutic monitoring in this pathology. This paper reviews the recent advances as well as the potential place of a more specific radiopharmaceutical in MM.<\/jats:p>","DOI":"10.3390\/ijms18020445","type":"journal-article","created":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T11:07:24Z","timestamp":1487588844000},"page":"445","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients"],"prefix":"10.3390","volume":"18","author":[{"given":"Cl\u00e9ment","family":"Bailly","sequence":"first","affiliation":[{"name":"Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France"},{"name":"Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolphe","family":"Leforestier","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Jamet","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Carlier","sequence":"additional","affiliation":[{"name":"Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France"},{"name":"Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Bourgeois","sequence":"additional","affiliation":[{"name":"Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France"},{"name":"Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Gu\u00e9rard","sequence":"additional","affiliation":[{"name":"Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ch\u00e9rel","sequence":"additional","affiliation":[{"name":"Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France"},{"name":"Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Saint-Herblain, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[{"name":"Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France"},{"name":"Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France"},{"name":"Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Saint-Herblain, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bodet-Milin","sequence":"additional","affiliation":[{"name":"Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France"},{"name":"Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,2,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"Knop","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","article-title":"Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","article-title":"International Myeloma Workshop Consensus Panel 3 Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3","volume":"117","author":"Dimopoulos","year":"2011","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.7314\/APJCP.2014.15.22.9879","article-title":"A systematic review of MRI, scintigraphy, FDG-PET and PET\/CT for diagnosis of multiple myeloma related bone disease\u2014Which is best?","volume":"15","author":"Weng","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/RLU.0b013e31825b2071","article-title":"FDG PET or PET\/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: A systematic review and meta-analysis","volume":"37","author":"Lu","year":"2012","journal-title":"Clin. Nucl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2967\/jnumed.111.098830","article-title":"Imaging of multiple myeloma and related plasma cell dyscrasias","volume":"53","author":"Walker","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3324\/haematol.12654","article-title":"FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma","volume":"93","author":"Salaun","year":"2008","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-13-2910","article-title":"Impact of initial FDG-PET\/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma","volume":"20","author":"Fouquet","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1038\/bcj.2015.87","article-title":"Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: Identification of patients needing therapy","volume":"5","author":"Siontis","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1477-7819-5-68","article-title":"11C-choline vs. 18F-FDG PET\/CT in assessing bone involvement in patients with multiple myeloma","volume":"5","author":"Nanni","year":"2007","journal-title":"World J. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00259-016-3392-7","article-title":"18F-fluorocholine versus 18F-fluorodeoxyglucose for PET\/CT imaging in patients with suspected relapsing or progressive multiple myeloma: A pilot study","volume":"43","author":"Balogova","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7150\/thno.13921","article-title":"11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement","volume":"6","author":"Lapa","year":"2016","journal-title":"Theranostics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12149-014-0931-9","article-title":"Comparison of 11C-4\u2019-thiothymidine, 11C-methionine, and 18F-FDG PET\/CT for the detection of active lesions of multiple myeloma","volume":"29","author":"Okasaki","year":"2015","journal-title":"Ann. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7150\/thno.11251","article-title":"Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging","volume":"5","author":"Wester","year":"2015","journal-title":"Theranostics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood.V124.21.3359.3359","article-title":"Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM\/DFCI 2009 Trial","volume":"124","author":"Moreau","year":"2014","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s00259-011-1738-8","article-title":"Value of 18F-fluorodeoxyglucose uptake in positron emission tomography\/computed tomography in predicting survival in multiple myeloma","volume":"38","author":"Haznedar","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/RLU.0000000000000696","article-title":"18F-FDG PET\/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: A comparative study","volume":"40","author":"Fonti","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","article-title":"Metabolic tumor volume assessed by 18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma","volume":"53","author":"Fonti","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"McDonald, J.E., Kessler, M.M., Gardner, M.W., Buros, A.F., Ntambi, J.A., Waheed, S., van Rhee, F., Zangari, M., Heuck, C., and Petty, N. (2016). Assessment of Total Lesion Glycolysis by 18F FDG PET\/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-16-0235"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/RLU.0b013e318266cee2","article-title":"The value of 18F-FDG PET\/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): Experience with 77 patients","volume":"38","author":"Nanni","year":"2013","journal-title":"Clin. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","article-title":"Image interpretation criteria for FDG PET\/CT in multiple myeloma: A new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe)","volume":"43","author":"Nanni","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.18632\/oncotarget.2290","article-title":"18FDG-PET\/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation","volume":"5","author":"Lapa","year":"2014","journal-title":"Oncotarget"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00259-014-2721-y","article-title":"PET\/CT studies of multiple myeloma using 18F-FDG and 18F-NaF: Comparison of distribution patterns and tracers\u2019 pharmacokinetics","volume":"41","author":"Sachpekidis","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00259-016-3502-6","article-title":"Treatment response evaluation with 18F-FDG PET\/CT and 18F-NaF PET\/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation","volume":"44","author":"Sachpekidis","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1007\/s00259-016-3458-6","article-title":"ImmunoPET to help stratify patients for targeted therapies and to improve drug development","volume":"43","author":"Bailly","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11302","DOI":"10.1039\/C5OB01618E","article-title":"New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and 64Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative","volume":"13","author":"Halime","year":"2015","journal-title":"Org. Biomol. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/2\/445\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:28:35Z","timestamp":1760207315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/2\/445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,18]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2]]}},"alternative-id":["ijms18020445"],"URL":"https:\/\/doi.org\/10.3390\/ijms18020445","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,18]]}}}